Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 24096545)

1.

QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer.

Zhang S, Shao Y, Hou G, Bai J, Yuan W, Hu L, Cheng T, Zetterberg A, Zhang J.

Tumour Biol. 2014 Mar;35(3):1847-54. doi: 10.1007/s13277-013-1246-5. Epub 2013 Oct 5.

PMID:
24096545
2.

Frequent amplifications and deletions of G1/S-phase transition genes, CCND1 and MYC in early breast cancers: a potential role in G1/S escape.

Jensen LB, Bartlett JM, Witton CJ, Kirkegaard T, Brown S, Müller S, Campbell F, Cooke TG, Nielsen KV.

Cancer Biomark. 2009;5(1):41-9. doi: 10.3233/CBM-2009-0570.

PMID:
19242061
3.

Multi-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients.

Li C, Bai J, Hao X, Zhang S, Hu Y, Zhang X, Yuan W, Hu L, Cheng T, Zetterberg A, Lee MH, Zhang J.

Cell Cycle. 2014;13(8):1299-305. doi: 10.4161/cc.28201. Epub 2014 Feb 28.

4.

TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.

Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, Gentien D, Barillot E, Roman-Roman S, Depil S, Cruzalegui F, Pierré A, Tucker GC, Dubois T.

PLoS One. 2013 May 20;8(5):e63712. doi: 10.1371/journal.pone.0063712. Print 2013.

5.

The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.

Jansson S, Bendahl PO, Grabau DA, Falck AK, Fernö M, Aaltonen K, Rydén L.

PLoS One. 2014 Jul 15;9(7):e102176. doi: 10.1371/journal.pone.0102176. eCollection 2014.

6.

MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.

Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, Zhao H, Yao W, Mi X, Wang E, Olopade OI, Wei M.

Tumour Biol. 2013 Dec;34(6):3945-58. doi: 10.1007/s13277-013-0983-9. Epub 2013 Jul 17.

PMID:
23860775
7.

Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.

Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M.

Hepatology. 1999 Jul;30(1):90-9.

PMID:
10385644
8.

Prognostic relevance of gene amplifications and coamplifications in breast cancer.

Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Köchli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G.

Cancer Res. 2004 Dec 1;64(23):8534-40.

9.

Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.

Gorgoulis VG, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M, Rassidakis A, Halazonetis TD, Field JK, Kittas C.

Am J Pathol. 1998 Dec;153(6):1749-65.

10.

Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.

Sugianto J, Sarode V, Peng Y.

Hum Pathol. 2014 Apr;45(4):802-9. doi: 10.1016/j.humpath.2013.11.013. Epub 2013 Dec 2.

PMID:
24560018
11.

Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression.

Naka T, Boltze C, Kuester D, Schulz TO, Schneider-Stock R, Kellner A, Samii A, Herold C, Ostertag H, Roessner A.

Cancer. 2005 Sep 15;104(6):1255-63.

12.

A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines.

Carson C, Omolo B, Chu H, Zhou Y, Sambade MJ, Peters EC, Tompkins P, Simpson DA, Thomas NE, Fan C, Sarasin A, Dessen P, Shields JM, Ibrahim JG, Kaufmann WK.

Pigment Cell Melanoma Res. 2012 Jul;25(4):514-26. doi: 10.1111/j.1755-148X.2012.01010.x. Epub 2012 Jun 1.

13.

[Alterations of cell cycle regulating proteins: Rb, p21 and p16 in laryngeal cancer].

Pietruszewska W, Durko M, Kobos J.

Otolaryngol Pol. 2007;61(6):951-7. doi: 10.1016/S0030-6657(07)70559-0. Polish.

PMID:
18546941
15.
16.

Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest.

Sheahan S, Bellamy CO, Dunbar DR, Harrison DJ, Prost S.

BMC Cancer. 2007 Nov 19;7:215.

17.

Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.

Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C.

Cancer Res. 2000 Feb 15;60(4):1077-83.

18.

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.

Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, Ellis IO, Chan SY.

Ann Oncol. 2013 Nov;24(11):2801-7. doi: 10.1093/annonc/mdt277. Epub 2013 Aug 1.

19.

Regulation of cellular genes in a chromosomal context by the retinoblastoma tumor suppressor protein.

Buchmann AM, Swaminathan S, Thimmapaya B.

Mol Cell Biol. 1998 Aug;18(8):4565-76.

20.

Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations.

Kim YH, Lachuer J, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nobusawa S, Nakazato Y, Tanaka Y, Vital A, Mariani L, Ohgaki H.

Brain Pathol. 2011 Nov;21(6):645-51. doi: 10.1111/j.1750-3639.2011.00492.x. Epub 2011 May 30.

PMID:
21470325
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk